ESG401

DRUG3 trials

Conditions

Metastatic Breast CancerNeoplasm of StomachNeoplasms, BladderNeoplasms, BreastNeoplasms, LungNeoplasms,ColorectalNeoplasms,OvarianTriple-Negative Breast Cancer (TNBC)

Phase 1

Study of ESG401 in Adults With Solid Tumors

CompletedNCT04892342

Shanghai Escugen Biotechnology Co., LtdNeoplasm of Stomach, Neoplasms, Bladder, Neoplasms, Breast +3

Start: 2021-09-14End: 2025-06-30Updated: 2025-09-12

Phase 3

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

RecruitingNCT06383767

Qilu Pharmaceutical Co., Ltd.Metastatic Breast Cancer

Start: 2024-07-11End: 2028-07-31Target: 378Updated: 2025-06-19

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

RecruitingNCT06732323

Qilu Pharmaceutical Co., Ltd.Triple-Negative Breast Cancer (TNBC)

Start: 2025-09-04End: 2028-07-31Target: 504Updated: 2025-09-23

Journal of Clinical Oncology2025-05-28

Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option<sup>☆</sup>.

2025-05-12

Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors.

2024-08-307 citations

Updated efficacy of anti-TROP2 ADC ESG401 for first-line metastatic TNBC in phase 1b study.

Journal of Clinical Oncology2024-08-101 citations

ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).

Journal of Clinical Oncology2024-06-014 citations

Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.

Journal of Clinical Oncology2023-06-017 citations

ESG401

Sponsors

Conditions

Phase 1

Phase 3

Related Papers